New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 8, 2013
11:17 EDTONCY, TRP, NUAN, LNKD, ETRMHigh option volume stocks; ETRM NUAN ONCY LNKD TRP
News For ETRM;NUAN;ONCY;LNKD;TRP From The Last 14 Days
Check below for free stories on ETRM;NUAN;ONCY;LNKD;TRP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 21, 2014
10:01 EDTTRPOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:42 EDTTRPTransCanada CEO says 'disappointed and frustrated' with Keystone delay
Subscribe for More Information
05:59 EDTTRPTransCanada downgraded to Sector Performer from Outperformer at CIBC
CIBC downgraded TransCanada to Sector Performer after the Keystone pipeline decision was delayed again.
05:59 EDTTRPState Department extends deadline for Keystone Pipeline Project
Subscribe for More Information
April 18, 2014
09:47 EDTLNKDLinkedIn announces 300M members reached worldwide
Subscribe for More Information
April 17, 2014
12:07 EDTTRPTransCanada downgraded to Hold from Buy at Canaccord
Subscribe for More Information
April 14, 2014
10:02 EDTLNKDOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:42 EDTLNKDLinkedIn initiated with an Overweight at Atlantic Equities
Atlantic Equities believes the recent pullback in shares of LinkedIn has created an attractive entry point. The firm started shares with an Overweight rating and $240 price target.
06:49 EDTONCYOncolytics Biotech reports evaluation of clinical study with REOLYSIN
Oncolytics Biotech announced that Dr. Adel Jebar of the Leeds Institute of Cancer and Pathology, University of Leeds, presented a poster at the 8th Annual International Conference on Oncolytic Virus Therapeutics held in Oxford, UK. Researchers examined REOLYSIN in panels of both normal and malignant liver cells and administered either REOLYSIN or saline to SCID mice with HCV-positive HCC xenografts. The aims of the study were to assess interferon secretion in normal and malignant liver cells in response to reovirus infection; the effects of reovirus infection in normal and malignant liver cells on HBV and HCV proteins; and the anti-viral and anti-cancer effects of reovirus in vivo. Based on these results, the investigators are evaluating the conduct of a translation clinical study.
06:47 EDTONCYOncolytics Biotech collaborators present preclinical research on liver cancer
Oncolytics Biotech announced that Dr. Adel Jebar of the Leeds Institute of Cancer and Pathology, University of Leeds, presented a poster at the 8th Annual International Conference on Oncolytic Virus Therapeutics held in Oxford, UK. Researchers examined Reolysin in panels of both normal and malignant liver cells and administered either Reolysin or saline to SCID mice with HCV-positive HCC xenografts. The aims of the study were to assess interferon secretion in normal and malignant liver cells in response to reovirus infection; the effects of reovirus infection in normal and malignant liver cells on HBV and HCV proteins; and the anti-viral and anti-cancer effects of reovirus in vivo. The study results showed that reovirus infection of primary human liver cells and HCC lines induced a robust type I interferon response; that reovirus-conditioned media from both primary human liver cells and JHH1 cells potently inhibits HCV and HBV in vitro with these effects abrogated by the blockade of the type I interferon receptor and soluble interferon beta; and that reovirus inhibits HCC xenograft growth and HCV replication in vivo. The researchers concluded that the results described a novel dual anti-viral and anti-cancer mechanism for reovirus in HBV/HCV-positive HCC and that reovirus treatment of patients with HBV/HCV positive HCC will likely lead to the suppression, rather than exacerbation, of the underlying oncogenic viral infection. Based on these results, the investigators are evaluating the conduct of a translation clinical study.
06:33 EDTONCYOncolytics Biotech collaborators present head, neck cancer biomarker poster
Subscribe for More Information
April 11, 2014
08:00 EDTLNKDLinkedIn remains a favorite large cap name at Piper Jaffray
Piper Jaffray says LinkedIn remains one of its favorite long-term large cap names. The firm believes investors are overlooking two new opportunities for the company: the addition of Sales Solutions and the Ad API. Piper reiterates an Overweight rating on LinkedIn with a $270 price target.
06:47 EDTLNKDSamsung ups S5 incentives to fend off rivals, Bloomberg says
Subscribe for More Information
April 10, 2014
10:44 EDTLNKDStocks with call strike movement; FSLR LNKD
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use